- Home
- PTON vs ZLAB Comparison
PTON vs ZLAB Comparison
Compare PTON & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PTON | ZLAB |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | 2019 | 2017 |
Fundamental Metrics
Financial Performance| Metric | PTON | ZLAB |
|---|---|---|
| Price | $5.70 | $18.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 5 |
| Target Price | $7.89 | ★ $49.60 |
| AVG Volume (30 Days) | ★ 14.8M | 867.0K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.13 | 38.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $460,156,000.00 |
| Revenue This Year | N/A | $9.75 |
| Revenue Next Year | $0.44 | $26.03 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 15.33 |
| 52 Week Low | $3.65 | $15.96 |
| 52 Week High | $9.20 | $41.20 |
Technical Indicators
Market Signals| Indicator | PTON | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 50.28 | 52.14 |
| Support Level | $5.45 | $18.29 |
| Resistance Level | $6.01 | $19.49 |
| Average True Range (ATR) | 0.28 | 0.65 |
| MACD | -0.06 | 0.23 |
| Stochastic Oscillator | 17.89 | 77.19 |
Price Performance
Historical ComparisonAbout PTON Peloton Interactive Inc.
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product derives revenue from the portfolio of Connected Fitness Products and related accessories, as well as Precor-branded fitness products, delivery and installation services, Peloton Bike portfolio rental products, extended warranty agreements, branded apparel, and commercial service contracts. Subscription revenue is derived from monthly Subscription fees. The company generates maximum revenue from the Subscription segment. Geographically, the company derives a majority of its revenue from North America and the rest from International markets.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.